Vor Bio is licensing global rights a fusion protein that inhibits two targets to potentially treat the neuromuscular disorder ...

Alexion to present seven abstracts, including four oral presentations, from its leading rare neurology portfolio at EAN 2025: Cambridge, UK Monday, June 23, 2025, 13:00 Hrs [IST] ...

Zanubrutinib shows superior progression-free survival in chronic lymphocytic leukemia compared with acalabrutinib plus ...

AstraZeneca (AZ) has announced promising results from a late-stage study of its C5 complement inhibitor Ultomiris ...

DelveInsight’s “ Dermatomyositis Market Insight, Epidemiology, and Market Forecast – 2034 ” provides an in-depth analysis of the current landscape and future outlook of the DM market across major ...

"We are honored to welcome Dr. Ekuta to our Life Sciences Strategic Advisory Board," said Girish Pashilkar, CEO of BP Logix. ...

Detailed price information for Voyager Therapeut (VYGR-Q) from The Globe and Mail including charting and trades.

San Diego—May 19, 2025–Rady Children’s Institute for Genomic Medicine (RCIGM®) today announced that Alexion, AstraZeneca Rare Disease has signed on as the first Platinum member of the ...

Buying Alexion remains a “fantastic acquisition” for AstraZeneca, the Big Pharma’s CEO has said, even as the company takes a $753 million hit for abandoning one of the drugs from that ...

AstraZeneca has agreed to buy U.S. Alexion Pharmaceuticals for $39 billion, betting on rare diseases and immunology as the British drug company emerges as one of the leading developers of a COVID ...

The acquisition cost AstraZeneca up to $1 billion, with the addition of tiered royalties on sales.Alexion hopes to create new genetic therapies, improving their safety and efficacy; the portfolio will ...

(Reuters) -AstraZeneca said on Friday its Alexion unit had agreed to buy U.S. drugmaker Pfizer's early-stage rare disease gene therapy portfolio for up to $1 billion, plus royalties on sales, as ...